REFERENCES
1. Shatola A, Nguyen KN, Kamangar E, Daly ME. Spontaneous regression of non-small cell lung cancer: a case report and literature review. Cureus 2020;12:e6639.
2. Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF. Regression of hodgkin’s disease after measles. Lancet 1981;1:1112.
3. George D. The influence of complicating disease upon leukæmia. Am J Med Sci 1904;127:563-92.
4. Radha G, Lopus M. The spontaneous remission of cancer: current insights and therapeutic significance. Transl Oncol 2021;14:101166.
5. Alberts P, Tilgase A, Rasa A, Bandere K, Venskus D. The advent of oncolytic virotherapy in oncology: the rigvir® story. Eur J Pharmacol 2018;837:117-26.
6. Guo W, Song H. Development of gene therapeutics for head and neck cancer in China: from bench to bedside. Hum Gene Ther 2018;29:180-7.
7. Kaufman HL, Shalhout SZ, Iodice G. Talimogene laherparepvec: moving from first-in-class to best-in-class. Front Mol Biosci 2022;9:834841.
8. Sugawara K, Iwai M, Ito H, Tanaka M, Seto Y, Todo T. Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation. Mol Ther Oncolytics 2021;22:129-42.
9. Yun CO, Hong J, Yoon AR. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements. Front Immunol 2022;13:953410.
10. Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell Res 2019;29:347-64.
11. Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol 2018;18:498-513.
12. Wang L, Chard Dunmall LS, Cheng Z, Wang Y. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment. J Immunother Cancer 2022;10:e004167.
13. Galluzzi L, Vitale I, Warren S, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer 2020;8:e000337.
14. Desfarges S, Ciuffi A. Viral integration and consequences on host gene expression. In: Witzany G, editor. Viruses: essential agents of life. Dordrecht: Springer Netherlands; 2012. pp. 147-75.
15. Wang B, Zhu J, Li D, et al. Newcastle disease virus infection induces activation of the NLRP3 inflammasome. Virology 2016;496:90-6.
16. Ginting TE, Christian S, Larasati YO, Suryatenggara J, Suriapranata IM, Mathew G. Antiviral interferons induced by Newcastle disease virus (NDV) drive A tumor-selective apoptosis. Sci Rep 2019;9:15160.
17. Wilden H, Fournier P, Zawatzky R, Schirrmacher V. Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. Int J Oncol 2009;34:971-82.
18. Xu Q, Rangaswamy US, Wang W, et al. Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo. Int J Cancer 2020;146:531-41.
19. Shao X, Wang X, Guo X, et al. STAT3 contributes to oncolytic newcastle disease virus-induced immunogenic cell death in melanoma cells. Front Oncol 2019;9:436.
20. Jarahian M, Watzl C, Fournier P, et al. Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol 2009;83:8108-21.
21. Liang Y, Song DZ, Liang S, Zhang ZF, Gao LX, Fan XH. The hemagglutinin-neuramidinase protein of Newcastle disease virus upregulates expression of the TRAIL gene in murine natural killer cells through the activation of Syk and NF-κB. PLoS One 2017;12:e0178746.
22. Burke S, Shergold A, Elder MJ, et al. Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses
23. Oseledchyk A, Ricca JM, Gigoux M, et al. Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. Oncotarget 2018;9:28702-16.
24. Zamarin D, Holmgaard RB, Subudhi SK, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 2014;6:226ra32.
25. Tanaka M, Shimbo T, Kikuchi Y, Matsuda M, Kaneda Y. Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon. Int J Cancer 2010;126:1982-91.
26. Matsushima-Miyagi T, Hatano K, Nomura M, et al. TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin Cancer Res 2012;18:6271-83.
27. Chandrahekhar P, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003;299:1033-6.
28. Fujihara A, Kurooka M, Miki T, Kaneda Y. Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother 2008;57:73-84.
29. Matveeva OV, Kochneva GV, Netesov SV, Onikienko SB, Chumakov PM. Mechanisms of oncolysis by paramyxovirus sendai. Acta Nat 2015;7:6-16.
30. Saga K, Kaneda Y. Oncolytic sendai virus-based virotherapy for cancer: recent advances. Oncolytic Virother 2015;4:141-7.
31. Achard C, Guillerme JB, Bruni D, et al. Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells. Oncoimmunology 2017;6:e1261240.
32. Tan DQ, Zhang L, Ohba K, Ye M, Ichiyama K, Yamamoto N. Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing. Eur J Immunol 2016;46:919-928.
33. Zhang Y, Patel B, Dey A, et al. Attenuated, oncolytic, but not wild-type measles virus infection has pleiotropic effects on human neutrophil function. J Immunol 2012;188:1002-10.
34. Berchtold S, Lampe J, Weiland T, et al. Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis. J Virol 2013;87:3484-501.
35. Aref S, Bailey K, Fielding A. Measles to the rescue: a review of oncolytic measles virus. Viruses 2016;8:294.
37. Donnelly OG, Errington-Mais F, Steele L, et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther 2013;20:7-15.
38. Rajaraman S, Canjuga D, Ghosh M, et al. Measles virus-based treatments trigger a pro-inflammatory cascade and a distinctive immunopeptidome in glioblastoma. Mol Ther Oncolytic 2019;12:147-61.
39. Guillerme JB, Boisgerault N, Roulois D, et al. Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res 2013;19:1147-58.
40. Gauvrit A, Brandler S, Sapede-Peroz C, Boisgerault N, Tangy F, Gregoire M. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res 2008;68:4882-92.
41. Boisgerault N, Guillerme JB, Pouliquen D, et al. Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas. Biomed Res Int 2013;2013:387362.
42. Wang B, Yan X, Guo Q, et al. Deficiency of caspase 3 in tumor xenograft impairs therapeutic effect of measles virus Edmoston strain. Oncotarget 2015;6:16019-30.
43. Javaheri A, Bykov Y, Mena I, García-Sastre A, Cuadrado-Castano S. Avian paramyxovirus 4 antitumor activity leads to complete remissions and long-term protective memory in preclinical melanoma and colon carcinoma models. Cancer Res Commun 2022;2:602-15.
44. Rieder M, Conzelmann KK. Rhabdovirus evasion of the interferon system. J Interferon Cytokine Res 2009;29:499-509.
45. Hornung V, Ellegast J, Kim S, et al. 5′-triphosphate RNA is the ligand for RIG-I. Science 2006;314:994-7.
46. Shi Z, Cai Z, Sanchez A, et al. A novel toll-like receptor that recognizes vesicular stomatitis virus. J Biol Chem 2011;286:4517-24.
47. Georgel P, Jiang Z, Kunz S, et al. Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway. Virology 2007;362:304-13.
48. Barchet W, Cella M, Odermatt B, Asselin-Paturel C, Colonna M, Kalinke U. Virus-induced interferon alpha production by a dendritic cell subset in the absence of feedback signaling
49. Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 2010;234:142-62.
50. Lund JM, Alexopoulou L, Sato A, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004;101:5598-603.
51. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801.
52. Melzer MK, Lopez-Martinez A, Altomonte J. Oncolytic vesicular stomatitis virus as a viro-immunotherapy: defeating cancer with a “hammer” and “anvil”. Biomedicines 2017;5:8.
53. Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol 2014;4:74.
54. Wongthida P, Diaz RM, Galivo F, et al. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res 2010;70:4539-49.
55. Diaz RM, Galivo F, Kottke T, et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 2007;67:2840-8.
56. Hastie E, Grdzelishvili VZ. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol 2012;93:2529-45.
57. Pol JG, Atherton MJ, Bridle BW, et al. Development and applications of oncolytic Maraba virus vaccines. Oncolytic Virother 2018;7:117-28.
58. Bourgeois-Daigneault MC, Roy DG, Aitken AS, et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci Transl Med 2018;10:eaao1641.
59. Atherton MJ, Stephenson KB, Tzelepis F, et al. Transforming the prostatic tumor microenvironment with oncolytic virotherapy. Oncoimmunology 2018;7:e1445459.
60. Place DE, Lee S, Kanneganti TD. PANoptosis in microbial infection. Curr Opin Microbiol 2021;59:42-9.
61. Masemann D, Köther K, Kuhlencord M, et al. Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages. Oncoimmunology 2018;7:e1423171.
62. Wei J, Waithman J, Lata R, et al. Influenza a infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion. J Immunol 2010;185:6013-22.
63. Rehwinkel J, Gack MU. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol 2020;20:537-51.
65. Burman B, Pesci G, Zamarin D. Newcastle disease virus at the forefront of cancer immunotherapy. Cancers 2020;12:3552.
66. Malogolovkin A, Gasanov N, Egorov A, Weener M, Ivanov R, Karabelsky A. Combinatorial approaches for cancer treatment using oncolytic viruses: projecting the perspectives through clinical trials outcomes. Viruses 2021;13:1271.
67. Schirrmacher V. Fifty years of clinical application of newcastle disease virus: time to celebrate! Biomedicines 2016;4:16.
68. Hines NL, Miller CL. Avian paramyxovirus serotype-1: a review of disease distribution, clinical symptoms, and laboratory diagnostics. Vet Med Int 2012;2012:708216.
69. Dortmans JC, Koch G, Rottier PJ, Peeters BP. Virulence of Newcastle disease virus: what is known so far? Vet Res 2011;42:122.
70. Panda A, Huang Z, Elankumaran S, Rockemann DD, Samal SK. Role of fusion protein cleavage site in the virulence of Newcastle disease virus. Microb Pathog 2004;36:1-10.
71. Cuadrado-Castano S, Sanchez-Aparicio MT, García-Sastre A, Villar E. The therapeutic effect of death: Newcastle disease virus and its antitumor potential. Virus Res 2015;209:56-66.
72. Zhang WX, Zuo EW, He Y, et al. Promoter structures and differential responses to viral and non-viral inducers of chicken melanoma differentiation-associated gene 5. Mol Immunol 2016;76:1-6.
73. Oh SW, Onomoto K, Wakimoto M, et al. Leader-containing uncapped viral transcript activates RIG-I in antiviral stress granules. PLoS Pathog 2016;12:e1005444.
74. Fournier P, Wilden H, Schirrmacher V. Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus. Int J Oncol 2012;40:287-98.
75. Kumar S, Ingle H, Mishra S, et al. IPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCE in type I interferons-dependent and -independent anticancer activity. Cell Death Dis 2015;6:e1758.
76. Schirrmacher V. Molecular mechanisms of anti-neoplastic and immune stimulatory properties of oncolytic newcastle disease virus. Biomedicines 2022;10:562.
77. Gao P, Chen L, Fan L, et al. Newcastle disease virus RNA-induced IL-1β expression via the NLRP3/caspase-1 inflammasome. Vet Res 2020;51:53.
78. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5:375-86.
79. Cuadrado-Castano S, Ayllon J, Mansour M, et al. Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models. Mol Cancer Ther 2015;14:1247-58.
80. Shan P, Tang B, Xie S, et al. NDV-D90 inhibits 17β-estradiol-mediated resistance to apoptosis by differentially modulating classic and nonclassic estrogen receptors in breast cancer cells. J Cell Biochem 2021;122:3-15.
81. Morla S, Kumar A, Kumar S. Newcastle disease virus mediated apoptosis and migration inhibition of human oral cancer cells: a probable role of β-catenin and matrix metalloproteinase-7. Sci Rep 2019;9:10882.
82. Wang JY, Chen H, Dai SZ, et al. Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3α Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity. J Immunother Cancer 2022;10:e003950.
83. Liao Y, Wang HX, Mao X, et al. RIP1 is a central signaling protein in regulation of TNF-α/TRAIL mediated apoptosis and necroptosis during Newcastle disease virus infection. Oncotarget 2017;8:43201-17.
84. Koks CA, Garg AD, Ehrhardt M, et al. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer 2015;136:E313-25.
85. Nan FL, Zheng W, Nan WL, et al. Newcastle disease virus inhibits the proliferation of T cells induced by dendritic cells
86. Zhao L, Niu C, Shi X, et al. Dendritic cells loaded with the lysate of tumor cells infected with Newcastle disease virus trigger potent anti-tumor immunity by promoting the secretion of IFN-γ and IL-2 from T cells. Oncol Lett 2018;16:1180-8.
87. Fournier P, Arnold A, Wilden H, Schirrmacher V. Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. Int J Oncol 2012;40:840-50.
88. Duong E, Fessenden TB, Lutz E, et al. Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Immunity 2022;55:308-323.e9.
89. Tan L, Zhang Y, Qiao C, et al. NDV entry into dendritic cells through macropinocytosis and suppression of T lymphocyte proliferation. Virology 2018;518:126-35.
90. Bai L, Koopmann J, Fiola C, Fournier P, Schirrmacher V. Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. Int J Oncol 2002;21:685-94.
91. Jensen S, Thomsen AR. Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. J Virol 2012;86:2900-10.
92. Bronte G, Petracci E, De Matteis S, et al. High levels of circulating monocytic myeloid-derived suppressive-like cells are associated with the primary resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: an exploratory analysis. Front Immunol 2022;13:866561.
93. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 2016;37:208-20.
94. Lim HX, Kim TS, Poh CL. Understanding the differentiation, expansion, recruitment and suppressive activities of myeloid-derived suppressor cells in cancers. Int J Mol Sci 2020;21:3599.
95. Meng G, Li B, Chen A, et al. Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma. Br J Cancer 2020;122:111-20.
96. Liang S, Lin X, Liang Y, Song D, Zhang L, Fan X. Killing Effects of IFN R-/- mouse NK cells activated by HN protein of NDV on mouse hepatoma cells and possible mechanism with Syk and NF-κB. Anat Rec 2019;302:1718-25.
97. Ricca JM, Oseledchyk A, Walther T, et al. Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy. Mol Ther 2018;26:1008-19.
98. Ge Z, Wu S, Zhang Z, Ding S. Mechanism of tumor cells escaping from immune surveillance of NK cells. Immunopharmacol Immunotoxicol 2020;42:187-98.
99. Zamarin D, Ricca JM, Sadekova S, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest 2018;128:1413-28.
100. Krabbe T, Marek J, Groll T, et al. Adoptive T cell therapy is complemented by oncolytic virotherapy with fusogenic VSV-NDV in combination treatment of murine melanoma. Cancers 2021;13:1044.
101. Matveeva OV, Guo ZS, Shabalina SA, Chumakov PM. Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency. Mol Ther Oncolytics 2015;2:15011.
102. Termeer CC, Schirrmacher V, Bröcker EB, Becker JC. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther 2000;7:316-23.
103. Ertel C, Millar NS, Emmerson PT, Schirrmacher V, von Hoegen P. Viral hemagglutinin augments peptide-specific cytotoxic T cell responses. Eur J Immunol 1993;23:2592-6.
104. González-Navajas JM, Fan DD, Yang S, et al. The impact of tregs on the anticancer immunity and the efficacy of immune checkpoint inhibitor therapies. Front Immunol 2021;12:625783.
105. Duc Dang A, Dinh Vu T, Hai Vu H, et al. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Vaccine 2022;40:3621-32.
106. Millar EV, Bennett JW, Barin B, et al. Safety, immunogenicity, and efficacy of NDV-3A against Staphylococcus aureus colonization: a phase 2 vaccine trial among US Army Infantry trainees. Vaccine 2021;39:3179-88.
107. Meng Q, He J, Zhong L, Zhao Y. Advances in the study of antitumour immunotherapy for newcastle disease virus. Int J Med Sci 2021;18:2294-302.
108. Wheelock EF, Dingle JH. Observations on the repeated administration of viruses to a patient with acute leukemia. N Engl J Med 1964;271:645-51.
109. AstraZeneca. An open-label, phase 1 study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of MEDI9253, a recombinant Newcastle disease virus encoding interleukin-12, in combination with durvalumab in participants with select advanced/metastatic solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT04613492 [Last accessed on 3 Apr 2023].
110. Long JS, Mistry B, Haslam SM, Barclay WS. Host and viral determinants of influenza a virus species specificity. Nat Rev Microbiol 2019;17:67-81.
112. Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol 2014;14:315-28.
113. Ryu S, Cowling BJ. Human influenza epidemiology. Cold Spring Harb Perspect Med 2021;11:a038356.
114. Nuwarda RF, Alharbi AA, Kayser V. An overview of influenza viruses and vaccines. Vaccines 2021;9:1032.
115. Kasloff SB, Pizzuto MS, Silic-Benussi M, Pavone S, Ciminale V, Capua I. Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines. J Virol 2014;88:9321-34.
116. Gao Q, Palese P. Rewiring the RNAs of influenza virus to prevent reassortment. Proc Natl Acad Sci USA 2009;106:15891-6.
117. Mehrbod P, Ande SR, Alizadeh J, et al. The roles of apoptosis, autophagy and unfolded protein response in arbovirus, influenza virus, and HIV infections. Virulence 2019;10:376-413.
118. Atkin-Smith GK, Duan M, Chen W, Poon IKH. The induction and consequences of influenza a virus-induced cell death. Cell Death Dis 2018;9:1002.
119. Lee S, Hirohama M, Noguchi M, Nagata K, Kawaguchi A. Influenza a virus infection triggers pyroptosis and apoptosis of respiratory epithelial cells through the type I interferon signaling pathway in a mutually exclusive manner. J Virol 2018;92:e00396-18.
120. Zhirnov OP, Konakova TE, Wolff T, Klenk HD. NS1 protein of influenza a virus down-regulates apoptosis. J Virol 2002;76:1617-25.
121. Brydon EW, Morris SJ, Sweet C. Role of apoptosis and cytokines in influenza virus morbidity. FEMS Microbiol Rev 2005;29:837-50.
122. Lu X, Masic A, Li Y, Shin Y, Liu Q, Zhou Y. The PI3K/Akt pathway inhibits influenza a virus-induced Bax-mediated apoptosis by negatively regulating the JNK pathway via ASK1. J Gen Virol 2010;91:1439-49.
124. Xie Y, Zhao Y, Shi L, et al. Gut epithelial TSC1/mTOR controls RIPK3-dependent necroptosis in intestinal inflammation and cancer. J Clin Invest 2020;130:2111-28.
125. Choi ME, Price DR, Ryter SW, Choi AMK. Necroptosis: a crucial pathogenic mediator of human disease. JCI Insight 2019;4:128834.
126. Meng MB, Wang HH, Cui YL, et al. Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy. Oncotarget 2016;7:57391-413.
127. Park HH, Kim HR, Park SY, et al. RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment. Mol Cancer 2021;20:107.
128. Allen IC, Scull MA, Moore CB, et al. The NLRP3 inflammasome mediates
129. Lee C, Do HTT, Her J, Kim Y, Seo D, Rhee I. Inflammasome as a promising therapeutic target for cancer. Life Sci 2019;231:116593.
130. Hall K, Cruz P, Tinoco I Jr, Jovin TM, van de Sande JH. “Z-RNA”-a left-handed RNA double helix. Nature 1984;311:584-6.
131. Zhang T, Yin C, Boyd DF, et al. Influenza virus Z-RNAS induce ZBP1-mediated necroptosis. Cell 2020;180:1115-1129.e13.
132. Zheng M, Kanneganti TD. The regulation of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis). Immunol Rev 2020;297:26-38.
133. Marcken M, Dhaliwal K, Danielsen AC, Gautron AS, Dominguez-Villar M. TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection. Sci Signal 2019;12:eaaw1347.
134. Bailey SR, Nelson MH, Himes RA, Li Z, Mehrotra S, Paulos CM. Th17 cells in cancer: the ultimate identity crisis. Front Immunol 2014;5:276.
135. Le Goffic R, Balloy V, Lagranderie M, et al. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza a virus-induced acute pneumonia. PLoS Pathog 2006;2:e53.
136. Guillot L, Le Goffic R, Bloch S, et al. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza a virus. J Biol Chem 2005;280:5571-80.
137. Bianchi F, Alexiadis S, Camisaschi C, et al. TLR3 expression induces apoptosis in human non-small-cell lung cancer. Int J Mol Sci 2020;21:1440.
138. Yang R, Yu S, Xu T, Zhang J, Wu S. Emerging role of RNA sensors in tumor microenvironment and immunotherapy. J Hematol Oncol 2022;15:43.
139. Weiss R, Sachet M, Zinngrebe J, et al. IL-24 sensitizes tumor cells to TLR3-mediated apoptosis. Cell Death Differ 2013;20:823-33.
140. Lomphithak T, Choksi S, Mutirangura A, et al. Receptor-interacting protein kinase 1 is a key mediator in TLR3 ligand and Smac mimetic-induced cell death and suppresses TLR3 ligand-promoted invasion in cholangiocarcinoma. Cell Commun Signal 2020;18:161.
141. Petersen SL, Peyton M, Minna JD, Wang X. Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression. Proc Natl Acad Sci USA 2010;107:11936-41.
142. Olschläger V, Pleschka S, Fischer T, et al. Lung-specific expression of active Raf kinase results in increased mortality of influenza a virus-infected mice. Oncogene 2004;23:6639-46.
143. Ji ZX, Wang XQ, Liu XF. NS1: a key protein in the “game” between influenza a virus and host in innate immunity. Front Cell Infect Microbiol 2021;11:670177.
144. García-Sastre A. Induction and evasion of type I interferon responses by influenza viruses. Virus Res 2011;162:12-8.
145. Tisoncik JR, Billharz R, Burmakina S, et al. The NS1 protein of influenza a virus suppresses interferon-regulated activation of antigen-presentation and immune-proteasome pathways. J Gen Virol 2011;92:2093-104.
146. Baskin CR, Bielefeldt-Ohmann H, García-Sastre A, et al. Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus. J Virol 2007;81:11817-27.
147. Muster T, Rajtarova J, Sachet M, et al. Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants. Int J Cancer 2004;110:15-21.
148. van Rikxoort M, Michaelis M, Wolschek M, et al. Oncolytic effects of a novel influenza a virus expressing interleukin-15 from the NS reading frame. PLoS One 2012;7:e36506.
149. Haye K, Burmakina S, Moran T, García-Sastre A, Fernandez-Sesma A. The NS1 protein of a human influenza virus inhibits type I interferon production and the induction of antiviral responses in primary human dendritic and respiratory epithelial cells. J Virol 2009;83:6849-62.
150. Hock K, Laengle J, Kuznetsova I, et al. Oncolytic influenza a virus expressing interleukin-15 decreases tumor growth
151. Kabiljo J, Laengle J, Bergmann M. From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruses. Cell Death Discov 2020;6:48.
152. Geiss GK, Salvatore M, Tumpey TM, et al. Cellular transcriptional profiling in influenza a virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci USA 2002;99:10736-41.
153. Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS. Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer 2018;6:140.
154. Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 2021;22:107-17.
155. Evgin L, Kottke T, Tonne J, et al. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci Transl Med 2022;14:eabn2231.
156. Tanoue K, Rosewell Shaw A, Watanabe N, et al. Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors. Cancer Res 2017;77:2040-51.
157. Watanabe K, Luo Y, Da T, et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight 2018;3:e99573.
158. Tang X, Li Y, Ma J, et al. Adenovirus-mediated specific tumor tagging facilitates CAR-T therapy against antigen-mismatched solid tumors. Cancer Lett 2020;487:1-9.
159. Svensson-Arvelund J, Cuadrado-Castano S, Pantsulaia G, et al. Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity. Nat Commun 2022;13:7149.
160. Guo ZS, Lu B, Guo Z, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer 2019;7:6.
161. Moehler M, Heo J, Lee HC, et al. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology 2019;8:1615817.
162. Vijayakumar G, Palese P, Goff PH. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. EBioMedicine 2019;49:96-105.
163. Yamada T, Tateishi R, Iwai M, Koike K, Todo T. Neoadjuvant use of oncolytic herpes virus G47Δ enhances the antitumor efficacy of radiofrequency ablation. Mol Ther Oncolytics 2020;18:535-45.
164. Jarnagin WR, Zager JS, Klimstra D, et al. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection. Cancer Gene Ther 2003;10:215-23.
165. Niavarani SR, Lawson C, Boudaud M, Simard C, Tai LH. Oncolytic vesicular stomatitis virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8+ T-cell functionality. J Immunother Cancer 2020;8:e000465.
166. Bai F, Niu Z, Tian H, et al. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy. Immunol Lett 2014;159:36-46.
167. Xu X, Sun Q, Yu X, Zhao L. Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy. Virus Res 2017;233:35-41.
168. Syed Najmuddin SUF, Amin ZM, Tan SW, et al. Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells
169. Vijayakumar G, McCroskery S, Palese P. Engineering Newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines. J Virol 2020:94.
170. Bai FL, Yu YH, Tian H, et al. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Cancer Biol Ther 2014;15:1226-38.
171. Tian L, Liu T, Jiang S, et al. Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy. Gene Ther 2023;30:64-74.
172. Zamarin D, Holmgaard RB, Ricca J, et al. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun 2017;8:14340.
173. Harper J, Burke S, Travers J, et al. Recombinant Newcastle disease virus immunotherapy drives oncolytic effects and durable systemic antitumor immunity. Mol Cancer Ther 2021;20:1723-34.
174. Huang FY, Wang JY, Dai SZ, et al. A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity. J Immunother Cancer 2020;8:e000330.
175. Hamilton JR, Vijayakumar G, Palese P. A Recombinant antibody-expressing influenza virus delays tumor growth in a mouse model. Cell Rep 2018;22:1-7.
176. Penghui Y, Fang S, Ruilan W, et al. Oncolytic activity of a novel influenza a virus carrying granulocyte-macrophage colony-stimulating factor in hepatocellular carcinoma. Hum Gene Ther 2019;30:330-8.
